Furthermore, ctDNA is being developed as an adjunct to improve residual disease prediction and outcome.
or combinations based on biomarker subtypes defined by hormone receptor, HER2, and MammaPrint (70-gene signature) status.
I-SPY 2.2 will enable testing of emerging targeted agents and combinations of biologics and allow those agents to either be combined with less toxic chemotherapeutic regimens or to replace cytotoxic chemotherapy entirely when less toxic agents are sufficiently effective.
https://globalforum.diaglobal.org/issue/july-...e-outcome/